MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.12.24 | Market Closed - Börse Stuttgart 19:19:38 05/07/2024 BST | ||
| 0.43 EUR | +7.50% |
|
| Current month | -8.51% | ||
| 1 month | -6.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.43 | +7.50% |
| 04/07/24 | 0.4 | 0.00% |
| 03/07/24 | 0.4 | -11.11% |
| 02/07/24 | 0.45 | -2.17% |
| 01/07/24 | 0.46 | -2.13% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:19 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0BQN |
| ISIN | DE000MB0BQN9 |
| Date issued | 09/11/2022 |
| Strike | 400 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 1.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.69 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.03 € |
| Spread % | 6.38% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.9
USD
Average target price
316.4
USD
Spread / Average Target
+1.79%
- Stock Market
- Warrants
- Warrant
